Jazz Pharmaceuticals rises after Q1 earnings, with analysts focused on FDA decision and pipeline readouts

Jazz Pharmaceuticals shares rose after its first-quarter earnings call, supported by double-digit growth across promoted brands in sleep, epilepsy and oncology. The stock recently traded at $224.30, up from $212.26 before the earnings release. Management cited strong demand for Xywav, Epidiolex, Midevo and Zepzelca, with CEO Renée Galá saying commercial teams delivered double-digit growth across promoted brands and benefited from ongoing launches. The company also pointed to patient support programs and broader market penetration as contributors to revenue growth. Key investor focus areas include the timing and outcome of the FDA’s decision on ZYHERA for gastric cancer, interim and top-line data from pivotal studies for Midevo and zanidatumab, and competitive pressure on the sleep franchise from generics and new therapies. Business development execution and expansion into rare disease markets remain additional watch points.